Options Spotlight: Merck & Company, Inc.
This week’s edition of Options Spotlight takes a look at Merck & Company, Inc.
(
MER |
Quote |
Chart |
News |
PowerRating)
According to Hoover’s, Merck is a pharmaceutical giant with a number of blockbuster drugs in its medicine cabinent. Drugs treating ailments associated with bad eating habits — high cholesterol, hypertension, and heart failure — are among Merck’s biggest sellers. Its drugs include hypertension fighters Cozaar and Hyzaar and cholesterol combatants Vytorin, Zetia, and Zocor. Merck makes drugs in a broad range of other therapeutic areas as well: Propecia treats male pattern baldness, Singulair treats asthma, and Fosamax fights osteoporosis. In addition to pharmaceuticals, the company makes childhood and adult vaccines for such diseases as measles, mumps, hepatitis, and shingles. In 2006, Merck was awarded approval for its cervical cancer vaccine Gardasil.
In the Options Spotlight, I shine a light on what’s happening in the options world. In the case of Merck & Company, Inc., call activity has been brisk on the shares as investors attempt to call a bottom to the security’s downtrend. Has this stock’s decline finally reached an end? For a closer look at Merck and its sentiment backdrop, go to schaeffersresearch.com.
Newly revised and updated, Bernie Schaeffer’s home study program, “10 Days to Successful Options Trading,” provides a foundation for your options trading success. Includes easy-to-follow guide, CD, DVD, and a special report — Click here to learn more.
Copyright Schaeffer’s Investment Research. www.schaeffersresearch.com.